← Back to Screener
Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Price$1.21
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-17.63%
Price vs S&P 500 (4W)-6.91%
VGM Score42.47
Market Capitalization$83.22M
All Metrics
Book Value / Share (Quarterly)$0.14
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.13
Price vs S&P 500 (YTD)-17.18%
EPS (TTM)$-0.29
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$-0.29
EPS (Annual)$-0.33
ROI (Annual)-176.10%
Cash / Share (Quarterly)$0.16
ROA (Last FY)-141.84%
EBITD / Share (TTM)$-0.29
Cash Flow / Share (Annual)$-0.11
P/B Ratio16.77x
P/B Ratio (Quarterly)9.01x
Net Interest Coverage (TTM)-2.85x
ROA (TTM)-172.72%
EPS Incl Extra (Annual)$-0.33
Current Ratio (Annual)5.14x
Quick Ratio (Quarterly)6.72x
3-Month Avg Trading Volume0.13M
52-Week Price Return-39.80%
52-Week High$3.10
EPS Excl Extra (Annual)$-0.33
26-Week Price Return-9.70%
Quick Ratio (Annual)5.10x
13-Week Price Return-6.92%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.00x
Enterprise Value$77.86M
Cash / Share (Annual)$0.21
3-Month Return Std Dev63.36%
ROE (Last FY)-176.10%
Net Interest Coverage (Annual)-1.45x
EPS Basic Excl Extra (Annual)$-0.33
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-0.29
ROI (TTM)-199.03%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-64.17%
Year-to-Date Return-9.02%
5-Day Price Return-3.20%
EPS Normalized (Annual)$-0.33
Month-to-Date Return-6.92%
EBITD / Share (Annual)$-0.33
EPS Basic Excl Extra (TTM)$-0.29
P/B Ratio (Annual)7.73x
Book Value / Share (Annual)$0.17
Price vs S&P 500 (13W)-15.18%
Beta0.77x
Revenue / Share (TTM)$0.00
ROE (TTM)-201.23%
52-Week Low$1.05
mGradeC
vgmGradeC
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TELOTelomir Pharmaceuticals, Inc. Common Stock | — | — | C | $1.21 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Telomir Pharmaceuticals is a preclinical-stage biopharmaceutical company developing Telomir-1, a small molecule designed to lengthen and protect telomeres, the protective DNA caps of chromosomes that shorten with age. The company aims to address age-related diseases—including Progeria, diabetes, cancer, Alzheimer's disease, and osteoarthritis—by targeting the underlying cellular mechanisms of aging rather than treating individual symptoms.